

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT SHARE PURCHASES PURSUANT TO SHARE AWARD SCHEME

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”) on a voluntary basis.

Reference is made to the announcement of the Company dated 18 August 2021 (the “**Announcement**”) in relation to the adoption of the share award scheme of the Company (the “**Share Award Scheme**”). Unless otherwise defined, capitalised terms used in this announcement have the same meanings as defined in the Announcement.

As instructed by the Company, the Trustee purchased an aggregate of 1,975,000 Shares (the “**Share Purchase**”) on the open market for the purpose of the Share Award Scheme. Details of the Shares purchased and the information about the Shares held by the Trustee on trust are as follows:

Date of purchases:	1 June 2023 to 16 June 2023
Total number of Shares purchased:	1,975,000 Shares
Percentage of the Shares purchased to the existing total number of Shares in issue as at the date of this announcement:	Approximately 0.205%
Average consideration per Share (excluding transaction costs):	Approximately HK\$0.9792
Total consideration of Shares purchased (excluding transaction costs):	Approximately HK\$1,933,850
Balance of number of Shares held by the Trustee	
– prior to the Share Purchase	2,325,000 Shares
– immediately after the Share Purchase:	4,300,000 Shares

Up to the date of this announcement, no Award Shares have been granted to any Selected Participants pursuant to the Share Award Scheme. The Board will from time to time review and determine at its absolute discretion such number of the Award Shares to be awarded to the Selected Participants with such vesting criteria and conditions as it may deem appropriate and the number of Shares to be further purchased on the open market for the purpose of the Share Award Scheme.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 16 June 2023

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.